Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 2/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30783468 | 1.00 | KLK7 (0.51) | KLK7KLK5MAPTPAX8TDP1 | |
| SCHEMBL31298691 | 0.94 | KLK7 (0.56) | KLK7KLK5MAPTPAX8TDP1 | |
| SCHEMBL27261434 | 0.93 | CPB1 (0.53) | KLK7KLK5MAPTPAX8TDP1 | |
| SCHEMBL30783505 | 0.91 | SIRT2 (0.54) | KLK7KLK5MAPT | |
| SCHEMBL27261452 | 0.91 | SIRT2 (0.54) | KLK7KLK5MAPT | |
| SCHEMBL29521507 | 0.88 | KLK7 (0.48) | KLK7KLK5MAPTPAX8TDP1 | |
| SCHEMBL26241451 | 0.88 | KLK7 (0.48) | KLK7KLK5MAPTPAX8TDP1 | |
| SCHEMBL24038748 | 0.88 | KLK7 (0.55) | KLK7KLK5MAPTPAX8TDP1 | |
| SCHEMBL29214548 | 0.88 | KLK7 (0.55) | KLK7KLK5MAPTPAX8TDP1 | |
| SCHEMBL31298652 | 0.87 | KLK7 (0.45) | KLK7KLK5MAPTPAX8TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034252-A1 | FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF | RATIO THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4561998-A1 | FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF | Ratio Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026072-A1 | FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF | RATIO THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034252-A1 | FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF | CCR6, OGFRL1, IL6ST | KLK7 4500/4885KLK5 4838/4885MAPT 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.